WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Consolidated revenue from operations stood at Rs. 111.05 crore
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Subscribe To Our Newsletter & Stay Updated